Search ARM

Advancing Innovation During COVID-19


ARM Global Regenerative & Advanced Therapy Medicine Sector Report: H1 2020

Despite the unprecedented global challenge presented by COVID-19, the regenerative medicine and advanced therapy sector demonstrated remarkable resilience in the first half of 2020. Patients continued to benefit from the cell and gene therapies currently on the market and in trials, and investment in the sector was robust. Policymakers and regulators recognize the need to continue to promote development for durable and potentially curative therapies for patients with unmet medical needs outside of COVID-19, though challenges remain. The H1 report provides an overview of the current financial, clinical, and policy landscape for these innovative treatments, with commentary from leading experts on the sector.


ARM Global Regenerative & Advanced Therapy Medicine Sector Report: H1 2020

Despite the unprecedented global challenge presented by COVID-19, the regenerative medicine and advanced therapy sector demonstrated remarkable resilience in the first half of 2020. Patients continued to benefit from the cell and gene therapies currently on the market and in trials, and investment in the sector was robust. Policymakers and regulators recognize the need to continue to promote development for durable and potentially curative therapies for patients with unmet medical needs outside of COVID-19, though challenges remain. The H1 report provides an overview of the current financial, clinical, and policy landscape for these innovative treatments, with commentary from leading experts on the sector.

Global Landscape

1,001+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

Financings

The amount raised in 2020 is on track to surpass that raised in 2018 – the strongest year for sector financings on record.

Total Global Financing

$10.7 Billion

120% YoY from H1 2019

Gene & Gene-modified
Cell Therapy

$7.9 Billion

81% YoY from H1 2019

Cell Therapy

$7.5 Billion

387% YoY from H1 2019

Tissue Engineering

$84 Million

25% YoY from H1 2019

Total Global Financings by Type

1,078

regenerative medicine & advanced therapy

clinical trials ongoing worldwide as of the

end of H1 2020

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

H1 2020

Gene Therapy
Cell-Based Immuno-Oncology
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: H1 2020